Stable and soluble antibodies inhibiting VEGF
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
C07K-016/22
C07K-001/00
C07K-007/06
출원번호
US-0708575
(2012-12-07)
등록번호
US-9090684
(2015-07-28)
발명자
/ 주소
Borras, Leonardo
Urech, David
Gunde, Tea
출원인 / 주소
Borras, Leonardo
인용정보
피인용 횟수 :
3인용 특허 :
40
초록▼
The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recom
The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
대표청구항▼
1. A method of inhibiting human VEGF-mediated endothelial cell proliferation and vascular permeability in a subject, comprising administering to the subject a composition comprising an antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) and a variable light chain (VL)
1. A method of inhibiting human VEGF-mediated endothelial cell proliferation and vascular permeability in a subject, comprising administering to the subject a composition comprising an antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) and a variable light chain (VL), wherein the VH comprises rabbit CDRH1, CDRH2 and CDRH3 sequences of SEQ ID NO: 8, SEQ ID NO: 20 and SEQ ID NO: 32, respectively, and the VL comprises rabbit CDRL1, CDRL2, and CDRL3 sequences of SEQ ID NO: 43, SEQ ID NO: 55 and SEQ ID NO: 66, respectively, wherein the antibody or antigen-binding fragment thereof neutralizes human VEGF in the subject. 2. The method of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds to human, rat, and mouse VEGF. 3. The method of claim 1, wherein the antigen-binding fragment is an scFv, a Fab fragment, a Fab′ fragment, or a F(ab′)2 fragment. 4. The method of claim 1, wherein the antibody or antigen-binding fragment thereof is formulated for topical, intraocular, oral, nasal, rectal or parental administration. 5. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 164 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 87. 6. The method of claim 5, wherein the antigen-binding fragment is an scFv, a Fab, a F(ab′)2, or a Fab′. 7. The method of claim 6, wherein the antigen-binding fragment is an scFv and the heavy chain variable region and the light chain variable region are linked by the sequence of SEQ ID NO: 181. 8. A method of inhibiting human VEGF-mediated endothelial cell proliferation and vascular permeability in a subjects, comprising administering to a subject a composition comprising an antibody or antigen-binding fragment thereof that comprises a variable heavy chain (VH) and a variable light chain (VL), wherein the VH comprises rabbit CDRH1, CDRH2 and CDRH3 sequences of SEQ ID NO: 8, SEQ ID NO: 20 and SEQ ID NO: 32, respectively, and the VL comprises rabbit CDRL1, CDRL2, and CDRL3 sequences of SEQ ID NO: 43, SEQ ID NO: 55 and SEQ ID NO: 66, respectively, wherein the antibody or antigen-binding fragment thereof neutralizes human VEGF in the subject, and wherein the composition is administered as a pharmaceutically acceptable dosage form.
Ladner Robert C. (Iamsville MD), Computer based system and method for determining and displaying possible chemical structures for converting double- or m.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Immunotheraphy using single chain polypeptide binding molecules.
Queen Cary L. (Los Altos CA) Schneider William P. (Mountain View CA) Selick Harold E. (Belmont CA), Polynucleotides encoding improved humanized immunoglobulins.
Huston James S. (Newton MA) Charette Marc F. (West Roxbury MA) Cohen Charles M. (Medway MA) Crea Roberto (Boston MA) Keck Peter C. (Millbury MA) Oppermann Hermann (Medway MA) Rueger David C. (West Ro, Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.